Choose Your Country or Region

c-Met

c-Met Products

All (57)
c-Met Inhibitors (46)
c-Met Antibodies (7)
New c-Met Products

Catalog No.	Product Name	Information	Product Use Citations	Product Validations
S1068	Crizotinib	Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Cancer Discov, 2024, OF1-OF20. Nat Commun, 2024, 15(1):1009 Nat Commun, 2024, 15(1):51
S1119	Cabozantinib (XL184)	Cabozantinib (XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.	Front Immunol, 2024, 15:1258475 Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249 Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249
S1112	SGX-523	SGX-523 is a selective Met (c-Met) inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.	PLoS Pathog, 2023, 19(8):e1011579 PLoS Pathog, 2023, 19(8):e1011579 Pharmacol Res Perspect, 2023, 11(1):e01047
S4001	Cabozantinib malate	Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.	Nat Neurosci, 2024, 10.1038/s41593-024-01604-8 Cancer Sci, 2023, 114(4):1651-1662 Cancer Sci, 2023, 114(4):1651-1662
S1111	Foretinib	Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.	Int J Mol Sci, 2023, 24(1)757 Biol Open, 2023, 12(8)bio059994 Melanoma Res, 2023, 10.1097/CMR.0000000000000911
S1070	PHA-665752	PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.	Acta Neuropathol, 2024, 147(1):44 J Biol Chem, 2024, 300(3):105762 Br J Cancer, 2023, 128(12):2186-2196
S2788	Capmatinib	Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.	World J Oncol, 2024, 15(3):492-505 J Thorac Oncol, 2023, 10.1016/j.jtho.2023.10.017 J Exp Clin Cancer Res, 2023, 10.1186/s13046-023-02866-z
S5190	Crizotinib hydrochloride	Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell-based assays, respectively. Crizotinib hydrochloride is also a potent ROS1 inhibitor with Ki less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Cancer Discov, 2023, 13(3):598-615 Nat Commun, 2023, 14(1):2829 Cancer Res Commun, 2023, 3(4):659-671
S1080	SU11274	SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. SU11274 induces autophagy, apoptosis and cell cycle arrest.	Cancer Cell Int, 2024, 24(1):43 J Transl Med, 2023, 21(1):530 J Transl Med, 2023, 21(1):530
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cancer Lett, 2024, 587:216692 Nat Commun, 2023, 14(1):4162 Oncogene, 2023, 42(21):1716-1727
S1114	JNJ-38877605	JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.	Gastric Cancer, 2024, 10.1007/s10120-024-01537-y Int J Mol Sci, 2023, 24(9)8086 Int J Mol Sci, 2023, 24(9)8086
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Front Cell Neurosci, 2024, 18:1441827 Mol Neurodegener, 2023, 18(1):31 Mol Neurodegener, 2023, 18(1):31
S2753	Tivantinib	Tivantinib is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.	Acta Neuropathol, 2024, 147(1):44 Eur J Cell Biol, 2024, 103(4):151457 Elife, 2023, 12e79432
S1094	PF-04217903	PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.	Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003 Neoplasia, 2019, 22(1):1-9 Sci Rep, 2019, 9(1):606
S1244	Amuvatinib (MP-470)	Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.	bioRxiv, 2024, 2023.11.21.568071 Microbiol Spectr, 2023, e0510522. J Pers Med, 2022, 12(2)258
S7067	Tepotinib	Tepotinib is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib (EMD 1214063) induces autophagy. Phase 1.	Oncogene, 2024, 10.1038/s41388-024-02987-5 Int J Mol Sci, 2024, 25(3)1769 Int J Mol Sci, 2024, 25(3)1769
S7674	Savolitinib (AZD6094)	Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.	Sci Rep, 2024, 14(1):20820 BMC Cancer, 2024, 24(1):357 Toxicol Appl Pharmacol, 2023, 475:116638
S1361	MGCD-265 analog	MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.	Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492 Protein Cell, 2019, 10(3):161-177
S2859	Golvatinib (E7050)	Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM). Phase 1/2.	Int J Mol Sci, 2023, 24(11)9606 Int J Mol Sci, 2022, 23(23)14884 Cancer Sci, 2020, 111(10):3813-3823
S7014	Merestinib (LY2801653)	Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. Merestinib (LY2801653) also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.	NPJ Breast Cancer, 2024, 10(1):65 Cancers (Basel), 2024, 16(12)2253 J Clin Invest, 2021, 131(11)146987
S9662	UNC2025	UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. UNC2025 also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.	Commun Biol, 2023, 6(1):916 Commun Biol, 2023, 6(1):916 Int J Mol Sci, 2023, 10.3390/ijms242115903
S8570	CEP-40783 (RXDX-106)	CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.	bioRxiv, 2023, 2023.10.20.563266 Mol Cancer Res, 2022, 20(4):542-555 J Oncol, 2022, 2022:2946929
S2774	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2.	Mol Carcinog, 2021, 60(7):481-496 G3 (Bethesda), 2021, 11(10)jkab265 Mol Cell Biochem, 2018, 449(1-2):1-8
S7669	NPS-1034	NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.	Nat Commun, 2023, 14(1):4162 J Med Chem, 2021, 64(6):3165-3184 Sci Rep, 2021, 11(1):19667
S8167	AMG 337	AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the Met (c-Met) receptor with an IC50 of 1 nM.	J Biol Chem, 2022, S0021-9258(22)00070-9 Cancer Cell, 2019, 36(1):35-50
S3759	Norcantharidin	Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.	Mol Med Rep, 2024, 29(5)71 Phytother Res, 2023, 10.1002/ptr.7963 Front Pharmacol, 2022, 13:1019478
S6412	Altiratinib	Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.	Theranostics, 2021, 11(20):9918-9936 Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
S5115	Sodium L-ascorbyl-2-phosphate	Sodium L-ascorbyl-2-phosphate (Sodium ascorbyl monophosphate, Sodium ascorbyl phosphate, SAP) is specifically produced for use as a stabilized source of vitamin C in cosmetic products. It is used in skin care recipes for UV protection, collagen production, as an antioxidant and for its skin lightening and brightening effects. Sodium L-ascorbyl-2-phosphate (2-Phospho-L-ascorbic acid trisodium salt, L-Ascorbic acid 2-phosphate trisodium salt, Sodium ascorbyl phosphate, SAP) is a selective antioxidant and a stimulator of hepatocyte growth factor (HGF) production.	Nature, 2022, 10.1038/s41586-022-04967-9 Stem Cell Res Ther, 2021, 12(1):48
S2201	BMS-794833	BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.	Cancer Res, 2021, canres.1428.2021
S2761	NVP-BVU972	NVP-BVU972 is a selective and potent Met (c-Met) inhibitor with IC50 of 14 nM.	PLoS Biol, 2021, 19(5):e3001263
S8404	S49076	S49076 is a novel, potent inhibitor of Met (c-Met), AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.	Mol Brain, 2020, 4;13(1):66
S1316	AMG-208	AMG 208 is a highly selective dual c-Met and RON inhibitor with IC50 of 9 nM for c-Met.
S2747	AMG-458	AMG 458 is a potent c-Met inhibitor with K_i of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
E4606^New	Dihexa	Dihexa(PNB-0408), an oligopeptide drug, is an orally active and blood-brain barrier-permeable analog of angiotensin IV. It binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at its receptor, c-Met. Dihexa can also be used as a therapeutic potential in the treatment of Alzheimer’s disease.
S0540	BAY-474	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
S8854	JNJ-38877618(OMO-1)	JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable Met (c-Met) kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant Met (c-Met) (2 and 3 nM IC50).
S9620	Elzovantinib (TPX-0022)	Elzovantinib (TPX-0022, CSF1R-IN-2) is a potent inhibitor of MET/CSF1R/SRC with enzymatic kinase inhibition IC50s of 0.14 nM, 0.71 nM and 0.12 nM, respectively. TPX-0022 modulates the tumor immune microenvironment in preclinical models.
A2467	Telisotuzumab (Anti-HGFR / c-Met)	Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.
A2468	Onartuzumab (Anti-HGFR / c-Met)	Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 144.64 KD.
A2469	Rilotumumab (Anti-HGF / SF)	Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD.
A2661	Ficlatuzumab (Anti-HGF / SF)	Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
A2662	Emibetuzumab (Anti-HGFR / c-Met)	Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.
S9308	Pulsatilla saponin D	Pulsatilla saponin D (SB365), isolated from the root of Pulsatilla koreana, targets c-Met and exerts antiangiogenic and antitumor activities.
S6870	Ningetinib	Ningetinib (CT-053, DE-120, CT053PTSA) is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib exhibits antitumor activity.
S0361	AMG-1	AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively.
A2930	Anti-HGF / SF (TAK-701)	Anti-HGF / SF (TAK-701) is a humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. It reverses gefitinib resistance in non-small-cell lung cancer. MW: 145.04 KD.
A2932	Anti-HGFR / c-Met (SAIT301)	Anti-HGFR / c-Met (SAIT301) is a humanized monoclonal antibody targeting the alpha chain of the extracellular domain of the human hepatocyte growth factor receptor (HGFR or c-Met) with potential antineoplastic activity. MW: 146.0 KD.
S6762	Bozitinib	Bozitinib is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.
S6764	Pamufetinib (TAS-115)	Pamufetinib (TAS-115) is a highly potent c-Met and VEGFR dual inhibitor with IC50s of 30 nM and 32 nM for recombinant VEGFR2 and recombinant MET, respectively.
E2655	Terevalefim	Terevalefim (ANG-3777), a small molecule hepatocyte growth factor (HGF) mimetic, induces c-MET dimerization and phosphorylation, reducing apoptosis and increasing cellular proliferation.
S7564	SAR125844	SAR125844 is a potent intravenously active and highly selective Met (c-Met) kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
E4914^New	Cabozantinib hydrochloride	Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
E1340^New	Glesatinib	Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).
S8676	Glumetinib	Glumetinib is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.	Cell Death Dis, 2024, 15(8):600
D4046	Telisotuzumab vedotin	Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours.
E0142	XL092	XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.
S1068	Crizotinib	Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively. It is also a potent ROS1 inhibitor with Ki value less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Cancer Discov, 2024, OF1-OF20. Nat Commun, 2024, 15(1):1009 Nat Commun, 2024, 15(1):51
S1119	Cabozantinib (XL184)	Cabozantinib (XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.	Front Immunol, 2024, 15:1258475 Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249 Biochim Biophys Acta Mol Basis Dis, 2024, 1870(6):167249
S1112	SGX-523	SGX-523 is a selective Met (c-Met) inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α. Phase 1.	PLoS Pathog, 2023, 19(8):e1011579 PLoS Pathog, 2023, 19(8):e1011579 Pharmacol Res Perspect, 2023, 11(1):e01047	3.">
S4001	Cabozantinib malate	Cabozantinib malate (XL184) is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret (c-Ret), Kit (c-Kit), Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively. Cabozantinib malate (XL184) induces apoptosis.	Nat Neurosci, 2024, 10.1038/s41593-024-01604-8 Cancer Sci, 2023, 114(4):1651-1662 Cancer Sci, 2023, 114(4):1651-1662
S1111	Foretinib	Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met (c-Met) and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Less potent against Ron, Flt-1/3/4, Kit (c-Kit), PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.	Int J Mol Sci, 2023, 24(1)757 Biol Open, 2023, 12(8)bio059994 Melanoma Res, 2023, 10.1097/CMR.0000000000000911
S1070	PHA-665752	PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM in cell-free assays, >50-fold selectivity for c-Met than RTKs or STKs.	Acta Neuropathol, 2024, 147(1):44 J Biol Chem, 2024, 300(3):105762 Br J Cancer, 2023, 128(12):2186-2196
S2788	Capmatinib	Capmatinib is a novel, ATP-competitive inhibitor of c-MET with IC50 of 0.13 nM in a cell-free assay, inactive against RONβ, as well as EGFR and HER-3. Capmatinib (INCB28060) inhibits Wnt/β-catenin and EMT signaling pathways and induces apoptosis in diffuse gastric cancer positive for c-MET amplification. Phase 1.	World J Oncol, 2024, 15(3):492-505 J Thorac Oncol, 2023, 10.1016/j.jtho.2023.10.017 J Exp Clin Cancer Res, 2023, 10.1186/s13046-023-02866-z
S5190	Crizotinib hydrochloride	Crizotinib (PF-02341066) hydrochloride (Xalkori) inhibits tyrosine phosphorylation of c-Met and nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) with IC50 of of 11 nM and 24 nM in cell-based assays, respectively. Crizotinib hydrochloride is also a potent ROS1 inhibitor with Ki less than 0.025 nM. Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.	Cancer Discov, 2023, 13(3):598-615 Nat Commun, 2023, 14(1):2829 Cancer Res Commun, 2023, 3(4):659-671
S1080	SU11274	SU11274 (PKI-SU11274) is a selective Met (c-Met) inhibitor with IC50 of 10 nM in cell-free assays, no effects on PGDFRβ, EGFR or Tie2. SU11274 induces autophagy, apoptosis and cell cycle arrest.	Cancer Cell Int, 2024, 24(1):43 J Transl Med, 2023, 21(1):530 J Transl Med, 2023, 21(1):530
S1561	BMS-777607	BMS-777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50 of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM in cell-free assays, 40-fold more selective for Met-related targets versus Lck, VEGFR-2, and TrkA/B, and more than 500-fold greater selectivity versus all other receptor and non receptor kinases.	Cancer Lett, 2024, 587:216692 Nat Commun, 2023, 14(1):4162 Oncogene, 2023, 42(21):1716-1727
S1114	JNJ-38877605	JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases. Phase 1.	Gastric Cancer, 2024, 10.1007/s10120-024-01537-y Int J Mol Sci, 2023, 24(9)8086 Int J Mol Sci, 2023, 24(9)8086
S1124	BMS-754807	BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.	Front Cell Neurosci, 2024, 18:1441827 Mol Neurodegener, 2023, 18(1):31 Mol Neurodegener, 2023, 18(1):31
S2753	Tivantinib	Tivantinib is the first non-ATP-competitive c-Met inhibitor with K_i of 0.355 μM in a cell-free assay, little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4. Tivantinib (ARQ 197) induces a G2/M arrest and apoptosis.	Acta Neuropathol, 2024, 147(1):44 Eur J Cell Biol, 2024, 103(4):151457 Elife, 2023, 12e79432
S1094	PF-04217903	PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM in A549 cell line, susceptible to oncogenic mutations (no activity to Y1230C mutant). Phase 1.	Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.003 Neoplasia, 2019, 22(1):1-9 Sci Rep, 2019, 9(1):606
S1244	Amuvatinib (MP-470)	Amuvatinib (MP-470, HPK 56) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively. Amuvatinib suppresses c-MET and c-RET. Amuvatinib is also active as a DNA repair protein Rad51 inhibitor with antineoplastic activity. Phase 2.	bioRxiv, 2024, 2023.11.21.568071 Microbiol Spectr, 2023, e0510522. J Pers Med, 2022, 12(2)258
S7067	Tepotinib	Tepotinib is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib (EMD 1214063) induces autophagy. Phase 1.	Oncogene, 2024, 10.1038/s41388-024-02987-5 Int J Mol Sci, 2024, 25(3)1769 Int J Mol Sci, 2024, 25(3)1769
S7674	Savolitinib (AZD6094)	Savolitinib (Volitinib, AZD6094, HMPL-504) is a novel, potent, and selective MET inhibitor currently in clinical development in various indications, including PRCC. The IC50 values of this compound for c-Met and p-Met are 5 nM and 3 nM, respectively. It shows exquisite selectivity for c-Met over 274 kinase.	Sci Rep, 2024, 14(1):20820 BMC Cancer, 2024, 24(1):357 Toxicol Appl Pharmacol, 2023, 475:116638
S1361	MGCD-265 analog	MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.	Cancer Cell, 2022, S1535-6108(22)00312-9 Cell Rep Med, 2022, 3(1):100492 Protein Cell, 2019, 10(3):161-177
S2859	Golvatinib (E7050)	Golvatinib (E7050) is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM, does not inhibit bFGF-stimulated HUVEC growth (up to 1000 nM). Phase 1/2.	Int J Mol Sci, 2023, 24(11)9606 Int J Mol Sci, 2022, 23(23)14884 Cancer Sci, 2020, 111(10):3813-3823
S7014	Merestinib (LY2801653)	Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. Merestinib (LY2801653) also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.	NPJ Breast Cancer, 2024, 10(1):65 Cancers (Basel), 2024, 16(12)2253 J Clin Invest, 2021, 131(11)146987
S9662	UNC2025	UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. UNC2025 also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.	Commun Biol, 2023, 6(1):916 Commun Biol, 2023, 6(1):916 Int J Mol Sci, 2023, 10.3390/ijms242115903
S8570	CEP-40783 (RXDX-106)	CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.	bioRxiv, 2023, 2023.10.20.563266 Mol Cancer Res, 2022, 20(4):542-555 J Oncol, 2022, 2022:2946929
S2774	MK-2461	MK-2461 is a potent, multi-targeted inhibitor for c-Met(WT/mutants) with IC50 of 0.4-2.5 nM, less potent to Ron, Flt1; 8- to 30-fold greater selectivity of c-Met targets versus FGFR1, FGFR2, FGFR3, PDGFRβ, KDR, Flt3, Flt4, TrkA, and TrkB. Phase 1/2.	Mol Carcinog, 2021, 60(7):481-496 G3 (Bethesda), 2021, 11(10)jkab265 Mol Cell Biochem, 2018, 449(1-2):1-8
S7669	NPS-1034	NPS-1034 is a dual Met (c-Met)/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.	Nat Commun, 2023, 14(1):4162 J Med Chem, 2021, 64(6):3165-3184 Sci Rep, 2021, 11(1):19667
S8167	AMG 337	AMG 337 is an oral, small molecule, ATP-competitive, highly selective inhibitor of the Met (c-Met) receptor with an IC50 of 1 nM.	J Biol Chem, 2022, S0021-9258(22)00070-9 Cancer Cell, 2019, 36(1):35-50
S3759	Norcantharidin	Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.	Mol Med Rep, 2024, 29(5)71 Phytother Res, 2023, 10.1002/ptr.7963 Front Pharmacol, 2022, 13:1019478
S6412	Altiratinib	Altiratinib (DCC-2701) is a potent single-digit nanomolar inhibitor of TRK, Met (c-Met), TIE2, and VEGFR2 kinases with IC50 vaules of 0.9 nM, 4.6 nM, and 0.8 nM for TRKA, B, and C, respectively. It inhibits Met (c-Met) and Met (c-Met) mutant with IC50 values in the range of 0.3-6 nM.	Theranostics, 2021, 11(20):9918-9936 Cold Spring Harb Mol Case Stud, 2021, 7(5)a006109
S2201	BMS-794833	BMS-794833 is a potent ATP competitive inhibitor of Met (c-Met)/VEGFR2 with IC50 of 1.7 nM/15 nM, also inhibits Ron, Axl and Flt3 with IC50 of <3 nM; a prodrug of BMS-817378. Phase 1.	Cancer Res, 2021, canres.1428.2021
S2761	NVP-BVU972	NVP-BVU972 is a selective and potent Met (c-Met) inhibitor with IC50 of 14 nM.	PLoS Biol, 2021, 19(5):e3001263
S8404	S49076	S49076 is a novel, potent inhibitor of Met (c-Met), AXL/MER, and FGFR1/2/3 with IC50 values below 20 nmol/L.	Mol Brain, 2020, 4;13(1):66
S1316	AMG-208	AMG 208 is a highly selective dual c-Met and RON inhibitor with IC50 of 9 nM for c-Met.
S2747	AMG-458	AMG 458 is a potent c-Met inhibitor with K_i of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
S6899	Licochalcone D	Licochalcone D (Lico D, LCD, LD), a flavonoid isolated from a Chinese medicinal plant Glycyrrhiza inflata, has antioxidant, anti-inflammatory and anti-cancer properties. Licochalcone D inhibit phosphorylation of NF-κB p65 in LPS signaling pathway. Licochalcone D inhibits JAK2, EGFR and Met (c-Met) activities and induces ROS-dependent apoptosis. Licochalcone D also induces caspases activation and poly (ADP-ribose) polymerase (PARP) cleavage.
S0540	BAY-474	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met and can act as an epigenetics probe.
S8854	JNJ-38877618(OMO-1)	JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable Met (c-Met) kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant Met (c-Met) (2 and 3 nM IC50).
S9620	Elzovantinib (TPX-0022)	Elzovantinib (TPX-0022, CSF1R-IN-2) is a potent inhibitor of MET/CSF1R/SRC with enzymatic kinase inhibition IC50s of 0.14 nM, 0.71 nM and 0.12 nM, respectively. TPX-0022 modulates the tumor immune microenvironment in preclinical models.
S9308	Pulsatilla saponin D	Pulsatilla saponin D (SB365), isolated from the root of Pulsatilla koreana, targets c-Met and exerts antiangiogenic and antitumor activities.
S6870	Ningetinib	Ningetinib (CT-053, DE-120, CT053PTSA) is a potent, orally bioavailable inhibitor of tyrosine kinase with IC50 of 6.7 nM, 1.9 nM and <1.0 nM for c-Met, VEGFR2 and Axl, respectively. Ningetinib exhibits antitumor activity.
S0361	AMG-1	AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively.
S6762	Bozitinib	Bozitinib is a highly selective ATP-competitive c-Met inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) selectively inhibits MET-altered tumor cells in preclinical models.
S6764	Pamufetinib (TAS-115)	Pamufetinib (TAS-115) is a highly potent c-Met and VEGFR dual inhibitor with IC50s of 30 nM and 32 nM for recombinant VEGFR2 and recombinant MET, respectively.
S7564	SAR125844	SAR125844 is a potent intravenously active and highly selective Met (c-Met) kinase inhibitor, displaying nanomolar activity against the wild-type kinase (IC50 value of 4.2 nmol/L) and H1094Y, Y1235D, M1250T, L1195V, and D1228H kinase domain mutants (IC50 values of 0.22, 1.7, 6.5, 65, and 81 nmol/L, respectively).
E4914^New	Cabozantinib hydrochloride	Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
E1340^New	Glesatinib	Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).
S8676	Glumetinib	Glumetinib is a potent and highly selective c-Met inhibitor with an IC50 of 0.42 ± 0.02 nmol/L. Glumetinib has greater than 2,400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, and TyrO3.	Cell Death Dis, 2024, 15(8):600
E0142	XL092	XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.
A2467	Telisotuzumab (Anti-HGFR / c-Met)	Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD.
A2468	Onartuzumab (Anti-HGFR / c-Met)	Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 144.64 KD.
A2469	Rilotumumab (Anti-HGF / SF)	Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD.
A2661	Ficlatuzumab (Anti-HGF / SF)	Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD.
A2662	Emibetuzumab (Anti-HGFR / c-Met)	Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.
A2930	Anti-HGF / SF (TAK-701)	Anti-HGF / SF (TAK-701) is a humanized monoclonal antibody directed against human hepatocyte growth factor (HGF) with potential antineoplastic activity. It reverses gefitinib resistance in non-small-cell lung cancer. MW: 145.04 KD.
A2932	Anti-HGFR / c-Met (SAIT301)	Anti-HGFR / c-Met (SAIT301) is a humanized monoclonal antibody targeting the alpha chain of the extracellular domain of the human hepatocyte growth factor receptor (HGFR or c-Met) with potential antineoplastic activity. MW: 146.0 KD.
E4606^New	Dihexa	Dihexa(PNB-0408), an oligopeptide drug, is an orally active and blood-brain barrier-permeable analog of angiotensin IV. It binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at its receptor, c-Met. Dihexa can also be used as a therapeutic potential in the treatment of Alzheimer’s disease.
E4914^New	Cabozantinib hydrochloride	Cabozantinib hydrochloride(XL184, BMS-907351 hydrochloride) is a potent small-molecule kinase inhibitor of c-MET and VEGFR2 with an IC50 of 1.3 nM, 0.035 nM respectively. It also inhibits RET, KIT, AXL, Tie2 and FLT3 with an IC50's of 5.2 nM, 4.6 nM, 7 nM, 14.3 nM, 11.3nM respectively. It can be promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
E1340^New	Glesatinib	Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).

Choose Selective c-Met Inhibitors

c-MetSignaling Pathway